The maximum allowable cost paid for antihemophilic Factor VII, VIII, IX and X products under the Medicaid program shall be the actual acquisition cost as reflected on the manufacturer’s invoice plus eight per cent plus the professional dispensing fee established for covered outpatient drugs.